[1]内科住院患者静脉血栓栓塞症预防中国专家建议写作组,中华医学会呼吸病学分会,中华医学会老年医学分会,等. 内科住院患者静脉血栓栓塞症预防中国专家建议(2015)[J]. 中华结核和呼吸杂志,2015,38:484-491. [2]Minet C, Potton L, Bonadona A, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis[J]. Crit Care, 2015,19:287. doi:10.1186/s13054-015-1003-9. [3]Malato A, Dentali F, Siragusa S, et al. The impact of deep vein thrombosis in critically ill patients: a Meta-analysis of major clinical outcomes[J]. Blood Transfus, 2015,13:559-568. [4]中国健康促进基金会血栓与血管专项基金专家委员会,中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会. 医院内静脉血栓栓塞症防治与管理建议[J]. 中华医学杂志,2018,98:1383-1388. [5]Tran A, Fernando SM, Rochwerg B, et al. Prognostic factors associated with development of venous thromboembolism in critically e patients-a systematic review and Meta-analysis[J]. Crit Care Med, 2022,50:e370-e381. [6]National Institute for Health and Care Excellence (NICE). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing[EB/OL]. (2023-08-02) [2024-01-15].https://www.nice.org.uk/guidance/ng158. [7]Chen X, Huang J, Liu J, et al. Venous thromboembolism risk factors and prophylaxis of elderly intensive care unit patients in a Chinese general hospital[J]. Ann Palliat Med, 2021,10:4453-4462. [8]Villiger R, Julliard P, Darbellay Farhoumand P, et al. Prediction of in-hospital bleeding in acutely ill medical patients: External validation of the IMPROVE bleeding risk score[J]. Thromb Res, 2023,230:37-44. [9]中国健康促进基金会血栓与血管专项基金专家委员会. 静脉血栓栓塞症机械预防中国专家共识[J]. 中华医学杂志,2020,100:484-492. [10]Liew NC, Alemany GV, Angchaisuksiri P, et al. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism[J]. Int Angiol, 2017,36:1-20. [11]Herring B, Lowen D, Ho P, et al. A systematic review of venous thromboembolism mechanical prophylaxis devices during surgery[J]. Langenbecks Arch Surg, 2023,408:410. doi:10.1007/s00423-023-03142-6. [12]Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for manage-ment of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients[J]. Blood Adv, 2018,2:3198-3225. [13]Fernando SM, Tran A, Cheng W, et al. VTE prophylaxis in critically Ⅲ adults: a systematic review and network Meta-analysis[J]. Chest, 2022,161:418-428. [14]DeBiase C, Giuliano CA, Doshi M, et al. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients[J]. Pharmacotherapy, 2021,41:424-429. [15]MacDougall K, Spyropoulos AC. New paradigms of extended thromboprophylaxis in medically Ill patients[J]. J Clin Med, 2020,9:1002. doi:10.3390/jcm9041002. [16]Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study[J]. Intensive Care Med, 2020,46:1089-1098. [17]Haykal T, Zayed Y, Dhillon H, et al. Meta-analysis of the role of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in critically Ill patients[J]. Int J Low Extrem Wounds, 2022,21:31-40. [18]Wang CM, Guo XF, Liu LM, et al. Prevention of deep vein thrombosis by panax notoginseng saponins combined with low-molecular-weight heparin in surgical patients[J]. Chin J Integr Med, 2022,28:771-778. [19]Eck RJ, Hulshof L, Wiersema R, et al. Incidence, prognostic factors, and outcomes of venous thromboembolism in critically ill patients: data from two prospective cohort studies[J]. Crit Care, 2021,25:27. doi:10.1186/s13054-021-03457-0. [20]Pannucci CJ, Fleming KI, Bertolaccini CB, et al. Assessment of anti-factor Xa levels of patients undergoing colorectal surgery given once-daily enoxaparin prophylaxis: a clinical study examining enoxaparin pharmacokinetics[J]. JAMA Surg, 2019,154:697-704. [21]Dutt T, Simcox D, Downey C, et al. Thromboprophylaxis in COVID-19: anti-FXa-the missing factor?[J]. Am J Respir Crit Care Med, 2020,202:455-457. [22]Rappold JF, Sheppard FR, Carmichael Ii SP, et al. Venous thromboembolism prophylaxis in the trauma intensive care unit: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document[J]. Trauma Surg Acute Care Open, 2021,6:e000643. doi:10.1136/tsaco-2020-000643. [23]Wu T, Xia X, Chen W, et al. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: a systematic review and Meta-analysis[J]. J Clin Pharm Ther, 2020,45:602-608. [24]Tran A, Fernando SM, Gates RS, et al. Efficacy and safety of anti-Xa-guided versus fixed dosing of low molecular weight heparin for prevention of venous thromboembolism in trauma patients: a systematic review and meta-analysis[J]. Ann Surg, 2023,277:734-741. [25]Karcutskie CA, Dharmaraja A, Patel J, et al. Association of anti-factor Xa-guided dosing of enoxaparin with venous thromboembolism after trauma[J]. JAMA Surg, 2018,153:144-149. [26]Saunders JA, Vazquez SR, Hill JA, et al. Clinical outcomes associated with anti-Xa-monitored enoxaparin for venous thromboembolism prophylaxis[J]. Pharmacotherapy, 2024,44:224-230. [27]Wang C, Ning YC, Song LP, et al. Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial[J]. BMJ Open, 2023,13:e069742. doi:10.1136/bmjopen-2022-069742. [28]Sahle BW, Pilcher D, Peter K, et al. Trends and risk factors for omission of early thromboprophylaxis in Australian and New Zealand ICUs between 2009 and 2020[J]. Intensive Care Med, 2022,48:590-598. [29]Helms J, Middeldorp S, Spyropoulos AC. Thromboprophylaxis in critical care[J]. Intensive Care Med, 2023,49:75-78. [30]中国老年医学学会重症医学分会,浙江省重症医学临床医学研究中心. 老年重症患者静脉血栓栓塞症预防中国专家共识(2023)[J]. 中华危重病急救医学,2023,35:561-572. |